The New England journal of medicine, 2019-02, Vol.380 (8), p.752-762
- Ridker, Paul M
- Everett, Brendan M
- Pradhan, Aruna
- MacFadyen, Jean G
- Solomon, Daniel H
- Zaharris, Elaine
- Mam, Virak
- Hasan, Ahmed
- Rosenberg, Yves
- Iturriaga, Erin
- Gupta, Milan
- Tsigoulis, Michelle
- Verma, Subodh
- Clearfield, Michael
- Libby, Peter
- Goldhaber, Samuel Z
- Seagle, Roger
- Ofori, Cyril
- Saklayen, Mohammad
- Butman, Samuel
- Singh, Narendra
- Le May, Michel
- Bertrand, Olivier
- Johnston, James
- Paynter, Nina P
- Glynn, Robert J
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Ridker, Paul M
- Everett, Brendan M
- Pradhan, Aruna
- MacFadyen, Jean G
- Solomon, Daniel H
- Zaharris, Elaine
- Mam, Virak
- Hasan, Ahmed
- Rosenberg, Yves
- Iturriaga, Erin
- Gupta, Milan
- Tsigoulis, Michelle
- Verma, Subodh
- Clearfield, Michael
- Libby, Peter
- Goldhaber, Samuel Z
- Seagle, Roger
- Ofori, Cyril
- Saklayen, Mohammad
- Butman, Samuel
- Singh, Narendra
- Le May, Michel
- Bertrand, Olivier
- Johnston, James
- Paynter, Nina P
- Glynn, Robert J
- Titel
- Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
- Ist Teil von
- The New England journal of medicine, 2019-02, Vol.380 (8), p.752-762
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with coronary artery disease were randomly assigned to either methotrexate (15 to 20 mg weekly) or placebo. At a median of 2.3 years, there was no difference between the two groups in the rate of myocardial infarction, stroke, or cardiovascular death.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1809798Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6587584
- Format
- –
- Schlagworte
- Aged, Angina, Arteriosclerosis, Atherosclerosis, Atherosclerosis - prevention & control, C-reactive protein, C-Reactive Protein - analysis, Cardiovascular disease, Cardiovascular Diseases - mortality, Cardiovascular Diseases - prevention & control, Cerebral infarction, Confidence Intervals, Coronary Artery Disease - complications, Coronary Artery Disease - drug therapy, Cytokines, Diabetes, Diabetes mellitus, Diabetes mellitus (non-insulin dependent), Diabetes Mellitus, Type 2 - complications, Disease prevention, Double-Blind Method, Double-blind studies, Drug dosages, Female, Folic acid, Follow-Up Studies, Health risk assessment, Heart attacks, Heart diseases, Hematocrit, Humans, IL-1β, Immunosuppressive Agents - administration & dosage, Immunosuppressive Agents - adverse effects, Inflammation, Interleukin 6, Interleukin-1beta - blood, Interleukin-6 - blood, Investigations, Liver, Male, Metabolic syndrome, Metabolic Syndrome - complications, Methotrexate, Methotrexate - administration & dosage, Methotrexate - adverse effects, Middle Aged, Monoclonal antibodies, Myocardial infarction, Myocardial Infarction - complications, Myocardial Infarction - drug therapy, Patients, Pharmaceuticals, Proportional Hazards Models, Proteins, Rheumatoid arthritis, Skin cancer, Statistics, Nonparametric, Stroke - etiology, Stroke - prevention & control, Transaminases - blood